Correspondence 0001628280-23-002542 from Mineralys Therapeutics, Inc. (MLYS) (CIK 0001933414) (MLYS)
Mineralys Therapeutics, Inc. (MLYS) (CIK 0001933414)
Date: Feb. 7, 2023 · CIK: 0001933414 · Accession: 0001628280-23-002542
AI Filing Summary & Sentiment
File numbers found in text: 333-269282
Letter
Re: Mineralys Therapeutics, Inc.
Document
February 7, 2023
Office of Life Sciences
Division of Corporation Finance
U.S. Securities and Exchange Commission
100 F Street N.E.
Washington, D.C. 20549
Registration Statement on Form S-1, as amended
File No. 333-269282
Ladies and Gentlemen:
In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Mineralys Therapeutics, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on Thursday, February 9, 2023, or as soon as practicable thereafter.
Pursuant to Rule 460 under the Act, please be advised that we have distributed approximately 4,210 copies of the Preliminary Prospectus dated February 2, 2023 (the “Preliminary Prospectus”) through the date hereof, to underwriters, dealers, institutions and others.
In connection with the Preliminary Prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement in Rule 15c2-8(b) under the Securities Exchange Act of 1934, as amended.
Very truly yours,
BOFA SECURITIES, INC.
Show Raw Text
CORRESP 1 filename1.htm Document February 7, 2023 Office of Life Sciences Division of Corporation Finance U.S. Securities and Exchange Commission 100 F Street N.E. Washington, D.C. 20549 Re: Mineralys Therapeutics, Inc. Registration Statement on Form S-1, as amended File No. 333-269282 Ladies and Gentlemen: In connection with the above-referenced Registration Statement, and pursuant to Rule 461 under the Securities Act of 1933, as amended (the “Act”), we hereby join in the request of Mineralys Therapeutics, Inc. that the effective date of the Registration Statement be accelerated so that it will be declared effective at 4:00 p.m., Eastern Time, on Thursday, February 9, 2023, or as soon as practicable thereafter. Pursuant to Rule 460 under the Act, please be advised that we have distributed approximately 4,210 copies of the Preliminary Prospectus dated February 2, 2023 (the “Preliminary Prospectus”) through the date hereof, to underwriters, dealers, institutions and others. In connection with the Preliminary Prospectus distribution for the above-referenced issue, the prospective underwriters have confirmed that they are complying with the 48-hour requirement in Rule 15c2-8(b) under the Securities Exchange Act of 1934, as amended. Very truly yours, BOFA SECURITIES, INC. EVERCORE GROUP L.L.C. STIFEL, NICOLAUS & COMPANY, INCORPORATED As Representatives of the several underwriters [Signature Pages Follow] BOFA SECURITIES, INC. By: /s/ Gerardo Ubaghs Name: Gerardo Ubaghs Title: Managing Director EVERCORE GROUP L.L.C. By: /s/ Gloria Tang Name: Gloria Tang Title: Managing Director STIFEL, NICOLAUS & COMPANY, INCORPORATED By: /s/ Kenneth Clausman Name: Kenneth Clausman Title: Managing Director As representatives of the several underwriters cc: Ilir Mujalovic, Shearman & Sterling LLP [Signature Page to Acceleration Request Letter]